Prostate Cancer Diagnostics Market
Prostate Cancer Diagnostics Market Forecasts to 2030 - Global Analysis By Test Type (Preliminary Tests, Confirmatory Tests, Immunohistochemistry and Other Test Types), Cancer Type (Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma and Other Cancer Types), End User (Hospitals, Outpatient Facilities, Diagnostic Laboratories, Cancer Research Institutes, Home Care, Research & Manufacturing and Other End Users) and by Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $8.77 BN |
|
Projected Year Value (2030) |
US $15.25 BN |
|
CAGR (2023 - 2030) |
8.23% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Prostate Cancer Diagnostics Market is accounted for $8.77 billion in 2023 and is expected to reach $15.25 billion by 2030 growing at a CAGR of 8.23% during the forecast period. In order to identify and describe prostate cancer in its early stages, prostate cancer diagnostics employ a multifaceted approach. Digital rectal examination (DRE), transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and the prostate-specific antigen (PSA) blood test are important diagnostic techniques. Moreover, the PSA test gauges the amount of a protein secreted by the prostate gland; high levels frequently signal the need for additional research. The evaluation of the prostate's size and texture is aided by a digital rectal examination.
According to the National Cancer Institute, in 2019, over 174,650 new cases of prostate cancer were diagnosed in the U.S. Additionally, data from the same source also suggests that over 31,620 deaths occurred in 2019 due to prostate cancer.
Market Dynamics:
Driver:
Growing prostate cancer incidence
Improved cancer detection techniques, aging populations, and altered lifestyles are the main causes of the prostate cancer incidence that has been rising steadily throughout the world. Furthermore, there is a growing need for sophisticated diagnostic tools that can precisely identify and characterize prostate cancer at its earliest stages, which is driving market growth as screening programs become more widely implemented and healthcare awareness increases.
Restraint:
Expensive neuroimaging equipment
Healthcare facilities face a major financial obstacle due to the prohibitive cost of sophisticated neuroimaging equipment, such as magnetic resonance imaging (MRI) machines. Access to advanced diagnostic tools may be restricted by the significant capital outlay necessary for purchasing and maintaining state-of-the-art machinery, especially in environments with limited resources. Additionally, it will take creative financing strategies and affordable substitutes to lessen this constraint.
Opportunity:
Technological developments in neuroimaging
The market is poised for substantial growth as long as neuroimaging technologies continue to progress. Advancements in diagnostic techniques like magnetoencephalography (MEG), positron emission tomography (PET), and functional magnetic resonance imaging (fMRI) present opportunities for increased sensitivity, resolution, and diagnostic power. Furthermore, putting money into research and development to incorporate these state-of-the-art technologies can lead to new opportunities for precise and thorough neuroimaging diagnosis.
Threat:
Threats from alternative diagnostic technologies
Traditional neuroimaging diagnostics are under threat from emerging alternative diagnostic technologies like wearable neurotechnology and cerebrospinal fluid biomarker analysis. Moreover, the market's established position is under threat from non-imaging modalities, so continued innovation and differentiation are necessary to stay relevant and hold onto market share.
Covid-19 Impact:
In the neuroimaging diagnostics market, the COVID-19 pandemic has had a significant effect. Healthcare services, such as regular diagnostic tests, elective screenings, and non-emergency medical visits, were disrupted by the abrupt start of the global health crisis. The application of social distancing measures and the allocation of resources to pandemic management led to a decrease in the use of neuroimaging diagnostics. Furthermore, healthcare facilities ability to make purchases was also impacted by supply chain disruptions and economic uncertainty, which caused delays in the purchase of cutting-edge imaging equipment.
The Prostatic Adenocarcinoma segment is expected to be the largest during the forecast period
The segment with the largest market share is prostate adenocarcinoma. The majority of cases of prostate cancer that are diagnosed are prostatic adenocarcinoma, which is the most common type of the disease. The prostate's glandular cells are the cancer's original site, and it can present in a variety of ways, both clinically and aggressively. Age, heredity, and hormonal influences are among the factors linked to the high incidence of prostatic adenocarcinoma. Moreover, prostatic adenocarcinoma is difficult to diagnose and characterize without the use of diagnostic techniques such as PSA testing, digital rectal examination (DRE), and advanced imaging technologies.
The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period
In the market, the segment with the highest CAGR is diagnostic laboratories. The need for early detection and rising disease prevalence are driving up demand for diagnostic services, which in turn is fueling the growth of diagnostic laboratories. These establishments are crucial in offering an extensive array of diagnostic examinations, such as biomarker evaluations and cancer screenings. Additionally, diagnostic laboratories are becoming increasingly important in the healthcare environment as a result of improvements in diagnostic technologies and a focus on personalized medicine.
Region with largest share:
Concerning prostate cancer diagnostics, North America holds the largest market share. Prostate cancer is very common in the area; cutting-edge diagnostic technologies were adopted early; and the region has a strong healthcare infrastructure. Furthermore, a reliable means of early detection and diagnosis is through robust screening programs, like PSA testing. Further strengthening North America's position is proactive approaches to cancer research, robust government backing, and high levels of public and professional awareness.
Region with highest CAGR:
In terms of the market for prostate cancer diagnostics, the Asia-Pacific region has the highest CAGR. The rising incidence of prostate cancer, growing knowledge of early detection, and the development of the healthcare system in nations like China, India, and Japan are some of the reasons driving this growth. The need for sophisticated diagnostics is being driven by the region's aging population and changing lifestyles, which are factors in the rising incidence of prostate cancer. Additionally, the adoption of cutting-edge diagnostic technologies is being accelerated by government initiatives, healthcare investments, and partnerships with multinational diagnostic companies.
Key players in the market
Some of the key players in Prostate Cancer Diagnostics market include Danaher Corporation, Abbott Laboratories, BioMerieux SA, F. Hoffman La Roche Ltd., Bayer Aktiengesellschaft, Myriad Genetics Inc., Genomic Health, Inc., Agilent Technologies, Siemens Healthcare GmbH, Vyant Bio Inc., Biocept Inc., DiaSorin S.p.A, AstraZeneca Plc., OPKO Health, Inc., Becton Dickinson and Company, MDx Health, Foundation Medicine Inc. and Telo Genomics Corp (3D Signatures).
Key Developments:
In December 2023, Danaher Corp., a global life sciences and diagnostics provider based in Washington D.C., has completed its $5.7 billion acquisition of Abcam plc, a supplier of protein research tools for life sciences based in Cambridge, England. Abcam has become an indirect wholly owned subsidiary of Danaher. Danaher’s Life Sciences businesses provide tools and technologies to support the advancement of pharmaceuticals and biopharmaceuticals.
In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.
In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.
Test Types Covered:
• Preliminary Tests
• Confirmatory Tests
• Immunohistochemistry
• Other Test Types
Cancer Types Covered:
• Benign Prostatic Hyperplasia
• Prostatic Adenocarcinoma
• Small Cell Carcinoma
• Other Cancer Types
End Users Covered:
• Hospitals
• Outpatient Facilities
• Diagnostic Laboratories
• Cancer Research Institutes
• Home Care
• Research & Manufacturing
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Prostate Cancer Diagnostics Market, By Test Type
5.1 Introduction
5.2 Preliminary Tests
5.2.1 PSA Tests
5.2.2 Free PSA Test
5.2.3 Total PSA Test
5.2.4 Other Preliminary Tests
5.3 Confirmatory Tests
5.3.1 Pca3 Test
5.3.2 Trans-Rectal Ultrasound
5.3.3 Biopsy Test
5.4 Immunohistochemistry
5.5 Other Test Types
6 Global Prostate Cancer Diagnostics Market, By Cancer Type
6.1 Introduction
6.2 Benign Prostatic Hyperplasia
6.3 Prostatic Adenocarcinoma
6.4 Small Cell Carcinoma
6.5 Other Cancer Types
7 Global Prostate Cancer Diagnostics Market, By End User
7.1 Introduction
7.2 Hospitals
7.3 Outpatient Facilities
7.4 Diagnostic Laboratories
7.5 Cancer Research Institutes
7.6 Home Care
7.7 Research & Manufacturing
7.8 Other End Users
8 Global Prostate Cancer Diagnostics Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Danaher Corporation
10.2 Abbott Laboratories
10.3 BioMerieux SA
10.4 F. Hoffman La Roche Ltd.
10.5 Bayer Aktiengesellschaft
10.6 Myriad Genetics Inc.
10.7 Genomic Health, Inc.
10.8 Agilent Technologies
10.9 Siemens Healthcare GmbH
10.10 Vyant Bio Inc.
10.11 Biocept Inc.
10.12 DiaSorin S.p.A
10.13 AstraZeneca Plc.
10.14 OPKO Health, Inc.
10.15 Becton Dickinson and Company
10.16 MDx Health
10.17 Foundation Medicine Inc.
10.18 Telo Genomics Corp (3D Signatures)
List of Tables
1 Global Prostate Cancer Diagnostics Market Outlook, By Region (2021-2030) ($MN)
2 Global Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
3 Global Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
4 Global Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
5 Global Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
6 Global Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
7 Global Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
8 Global Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
9 Global Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
10 Global Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
11 Global Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
12 Global Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
13 Global Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
14 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
15 Global Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
16 Global Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
17 Global Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
18 Global Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
19 Global Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
20 Global Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
21 Global Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
22 Global Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
23 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
24 Global Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
25 Global Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
26 Global Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
27 North America Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
28 North America Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
29 North America Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
30 North America Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
31 North America Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
32 North America Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
33 North America Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
34 North America Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
35 North America Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
36 North America Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
37 North America Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
38 North America Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
39 North America Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
40 North America Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
41 North America Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
42 North America Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
43 North America Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
44 North America Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
45 North America Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
46 North America Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
47 North America Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
48 North America Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
49 North America Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
50 North America Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
51 North America Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
52 North America Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
53 Europe Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
54 Europe Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
55 Europe Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
56 Europe Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
57 Europe Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
58 Europe Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
59 Europe Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
60 Europe Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
61 Europe Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
62 Europe Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
63 Europe Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
64 Europe Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
65 Europe Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
66 Europe Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
67 Europe Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
68 Europe Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
69 Europe Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
70 Europe Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
71 Europe Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
72 Europe Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
73 Europe Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
74 Europe Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
75 Europe Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
76 Europe Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
77 Europe Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
78 Europe Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
79 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
80 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
81 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
82 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
83 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
84 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
85 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
86 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
87 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
88 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
89 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
90 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
91 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
92 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
93 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
94 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
95 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
96 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
97 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
98 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
99 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
100 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
101 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
102 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
103 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
104 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
105 South America Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
106 South America Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
107 South America Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
108 South America Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
109 South America Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
110 South America Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
111 South America Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
112 South America Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
113 South America Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
114 South America Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
115 South America Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
116 South America Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
117 South America Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
118 South America Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
119 South America Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
120 South America Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
121 South America Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
122 South America Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
123 South America Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
124 South America Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
125 South America Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
126 South America Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
127 South America Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
128 South America Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
129 South America Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
130 South America Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
131 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
132 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
133 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
134 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
135 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
136 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
137 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
138 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
139 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
140 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
141 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
142 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
143 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
144 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
145 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
146 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
147 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
148 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
149 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
150 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
151 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
152 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
153 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
154 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
155 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
156 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
